Cargando…

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder

OBJECTIVE: To examine the urodynamic effects of fesoterodine on neurogenic detrusor overactivity and/or low compliance bladder. METHODS: A total of 77 patients (52 men, 25 women; aged 61.6 ± 20.3 years) were given fesoterodine 4–8 mg/day and prospectively followed for 12 weeks. The primary end‐point...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaga, Kanya, Yamanishi, Tomonori, Kaga, Mayuko, Fuse, Miki, Kamasako, Tomohiko, Ishizuka, Mitsuru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles: Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589380/ https://www.ncbi.nlm.nih.gov/pubmed/32767525 http://dx.doi.org/10.1111/iju.14319

Ejemplares similares

Efficacy of Transcutaneous Tibial Nerve Stimulation With Silver Spike Point® Electrodes for Refractory Overactive Bladder: A Single-Arm Study
por: Kaga, Kanya, et al.
Publicado: (2023)

The Efficacy of Compression Stockings on Patients With Nocturia: A Single-Arm Pilot Study
por: Kaga, Kanya, et al.
Publicado: (2022)

Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
por: Yamanishi, Tomonori, et al.
Publicado: (2020)

Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
por: Sano, Yamato, et al.
Publicado: (2023)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011)

A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study)
por: Yamanishi, Tomonori, et al.
Publicado: (2020)

Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model
por: Biardeau, Xavier, et al.
Publicado: (2017)

Role of fesoterodine in the treatment of overactive bladder
por: Mansfield, Kylie J
Publicado: (2009)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

Differences in the Urinary Microbiome of Patients with Overactive Bladder Syndrome with and without Detrusor Overactivity on Urodynamic Measurements
por: Javan Balegh Marand, Aida, et al.
Publicado: (2023)

Fesoterodine for the treatment of urinary incontinence and overactive bladder
por: Ellsworth, Pamela
Publicado: (2009)

Comparison of solifenacin and fesoterodine in treatment of overactive bladder
por: Ercan, Önder, et al.
Publicado: (2015)

Botulinum Toxin in Neurogenic Detrusor Overactivity
por: D'Ancona, Carlos Arturo Levi, et al.
Publicado: (2012)

Overactive bladder, differential diagnosis, and clinical utility of fesoterodine
por: Wyndaele, Jean-Jacques
Publicado: (2012)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

Safety and Tolerability of Fesoterodine in Older Adult Patients with Overactive Bladder
por: Heesakkers, John, et al.
Publicado: (2022)

Adaptive changes of telocytes in the urinary bladder of patients affected by neurogenic detrusor overactivity
por: Traini, Chiara, et al.
Publicado: (2017)

Patient treatment preferences for symptomatic refractory urodynamic idiopathic detrusor overactivity
por: Fontaine, Christina L., et al.
Publicado: (2017)

Acute effect of sacral neuromodulation for treatment of detrusor overactivity on urodynamic parameters
por: Groenendijk, Ilse M., et al.
Publicado: (2019)

Autologous and heterotopic transplantation of adipose stromal vascular fraction ameliorates stress urinary incontinence in rats with simulated childbirth trauma
por: Inoue, Ken-ichi, et al.
Publicado: (2017)

OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020)

Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder
por: Cardozo, Linda, et al.
Publicado: (2010)

Increased detrusor collagen is associated with detrusor overactivity and decreased bladder compliance in men with benign prostatic obstruction
por: Bellucci, Carlos H.S., et al.
Publicado: (2017)

Nerve sprouting and neurogenic inflammation characterize the neurogenic detrusor overactive bladder of patients no longer responsive to drug therapies
por: Traini, Chiara, et al.
Publicado: (2019)

Efficacy, according to urodynamics, of OnabotulinumtoxinA compared with antimuscarinic drugs, for neurogenic detrusor overactivity: a systematic review and network meta-analysis
por: Xu, Rui, et al.
Publicado: (2022)

The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin
por: Traini, Chiara, et al.
Publicado: (2019)

Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
por: Hui, C, et al.
Publicado: (2016)

Urodynamic evaluation in pediatric neurogenic bladder.
por: Kim, K. M., et al.
Publicado: (1993)

Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin
por: Ferreira, Ana, et al.
Publicado: (2023)

Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report
por: Kato, Taiki, et al.
Publicado: (2021)

Prevalence and urodynamic characteristics of detrusor overactivity with impaired contractility in the community-dwelling elderly with non-neurogenic lower urinary tract symptoms: Is it from a single or two independent bladder dysfunctions?
por: Jeong, Seong Jin, et al.
Publicado: (2021)

Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
por: Morris, Vikky, et al.
Publicado: (2014)

Inosine Improves Neurogenic Detrusor Overactivity following Spinal Cord Injury
por: Chung, Yeun Goo, et al.
Publicado: (2015)

Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity
por: Cho, Young Sam, et al.
Publicado: (2016)

Characterization of upper lamina propria interstitial cells in bladders from patients with neurogenic detrusor overactivity and bladder pain syndrome
por: Gevaert, Thomas, et al.
Publicado: (2011)

OAB score: A clinical model that predicts the probability of presenting overactive detrusor in the urodynamic study
por: Arribillaga, Leandro Cristian, et al.
Publicado: (2018)

Protocol for a phase II, open-label exploratory study investigating the efficacy of fesoterodine for treatment of adult patients with spinal cord injury suffering from neurogenic detrusor overactivity for amelioration of autonomic dysreflexia
por: Walter, Matthias, et al.
Publicado: (2018)

AB206. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
por: Chen, Hui, et al.
Publicado: (2016)

Follow-up urodynamics in patients with neurogenic bladder
por: Sinha, Sanjay
Publicado: (2017)

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
por: Wyndaele, J-J, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_e8katb8rrusp95h8slu5le8b5j